

Analyn Lizaso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4395062/publications.pdf>

Version: 2024-02-01

53
papers

964
citations

471061

17
h-index

525886

27
g-index

54
all docs

54
docs citations

54
times ranked

1343
citing authors

#	ARTICLE	IF	CITATIONS
1	Î²-adrenergic receptor-stimulated lipolysis requires the RAB7-mediated autolysosomal lipid degradation. <i>Autophagy</i> , 2013, 9, 1228-1243.	4.3	102
2	Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1369-1375.	0.5	68
3	Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing. <i>Histopathology</i> , 2019, 75, 890-899.	1.6	55
4	Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1027-1036.	0.5	55
5	Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer. <i>Aging</i> , 2020, 12, 3140-3155.	1.4	44
6	Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling. <i>Thoracic Cancer</i> , 2019, 10, 823-831.	0.8	39
7	A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung. <i>Modern Pathology</i> , 2020, 33, 626-638.	2.9	38
8	Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients. <i>Cancer Biology and Medicine</i> , 2019, 16, 556-564.	1.4	36
9	Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2517-2528.	2.0	34
10	The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. <i>Journal of Translational Medicine</i> , 2019, 17, 298.	1.8	33
11	Detection of Microsatellite Instability from Circulating Tumor DNA by Targeted Deep Sequencing. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 860-870.	1.2	33
12	The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. <i>Lung Cancer</i> , 2020, 146, 165-173.	0.9	32
13	Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. <i>Journal of International Medical Research</i> , 2020, 48, 030006051988727.	0.4	27
14	Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 935-944.	1.2	24
15	Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 103-112.	0.8	23
16	Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1023.	1.3	22
17	Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance. <i>Clinical Lung Cancer</i> , 2021, 22, e390-e394.	1.1	19
18	Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2020, 141, 199-208.	1.3	18

#	ARTICLE	IF	CITATIONS
37	SIM2 maintains innate host defense of the small intestine. American Journal of Physiology - Renal Physiology, 2014, 307, G1044-G1056.	1.6	5
38	The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment. Translational Lung Cancer Research, 2021, 10, 326-339.	1.3	5
39	Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC. Journal of Thoracic Oncology, 2021, 16, 349-351.	0.5	5
40	Efficacy of afatinib in a HER2 amplification-positive endometrioid adenocarcinoma patient—a case report. OncoTargets and Therapy, 2019, Volume 12, 5305-5309.	1.0	4
41	Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study. Lung Cancer, 2020, 150, 97-106.	0.9	4
42	Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report. Translational Lung Cancer Research, 2020, 9, 144-147.	1.3	4
43	Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review. Hereditary Cancer in Clinical Practice, 2021, 19, 7.	0.6	4
44	Differences in the clinicopathological characteristics of pure and mixed invasive micropapillary breast carcinomas from eastern China. Annals of Translational Medicine, 2021, 9, 412-412.	0.7	3
45	Targeted sequencing identifies the mutational signature of double primary and metastatic malignancies: a case report. Diagnostic Pathology, 2019, 14, 101.	0.9	2
46	Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients. Lung Cancer, 2020, 146, 209-216.	0.9	2
47	The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report. Annals of Translational Medicine, 2021, 9, 80-80.	0.7	2
48	The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report. Cancer Biology and Therapy, 2021, 22, 1-4.	1.5	2
49	A reply to “MET-mutant cancer and immune checkpoint inhibitors: A large database analysis”. Lung Cancer, 2020, 150, 259-260.	0.9	0
50	A reply to “ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis”. Lung Cancer, 2020, 150, 254-255.	0.9	0
51	Efficacy of Joungal in preventing febrile neutropenia induced by platinum-based doublet chemotherapy in lung cancer. Annals of Palliative Medicine, 2020, 9, 1688-1695.	0.5	0
52	Third left pulmonary lobe. Thorax, 2021, 76, 525-525.	2.7	0
53	A Burning External Colon Cancer Patient With Diffuse Miliary Peritoneal Metastases. American Journal of Gastroenterology, 2021, 116, 632-632.	0.2	0